pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,458 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1671Endpoints1316Fierce Biotech632BioSpace632BioPharma Dive494raps211onclive165fda recalls108fda medwatch
therapy area
allOncology11784Rare Disease2960Immunology2721Cardiology2405Pulmonology2054Hematology2004Vaccines1730Psychiatry & CNS1141
  • Republican pushback on methadone and buprenorphine raises concerns among addiction experts
    Recent guidance from the Trump administration has revived a debate over the use of methadone and buprenorphine for opioid addiction treatment, prompting renewed scrutiny of federal policy. Addicti…
    STAT · 4mo agoRegulatoryNegative↗ source
  • DOJ announces second settlement on youth gender-affirming care amid broader health news
    The Department of Justice disclosed that it has reached a second settlement with parties involved in providing gender-affirming care to minors. The agreement, announced in a recent newsletter, buil…
    STAT · 4mo agoRegulatoryNeutral↗ source
← prev
page 178 of 219
next →
100
globenewswire health73
fda press56
Ophthalmology906
Endocrinology & Metabolism729
Pain702
Nephrology698
  • ADA CEO apologizes for expelling five members over protest literature, vows review and trust rebuilding
    Five members of the American Diabetes Association were removed from its annual scientific sessions in New Orleans after distributing editorial material that criticized federal research funding cuts…
    STAT · 4mo agoNegative↗ source
  • ACOG issues new pregnancy vaccine schedule that diverges from CDC guidance
    The American College of Obstetricians and Gynecologists (ACOG) released a new vaccine schedule for pregnant individuals that differs from the current CDC guidance. ACOG recommends four vaccines be…
    STAT · 4mo agoNeutral↗ source
  • Nevada Supreme Court blocks enforcement of teen abortion notification law, expanding access
    The Nevada Supreme Court issued a unanimous order on May 28 that temporarily halts the enforcement of the state’s 1985 parental notification requirement for abortions. The preliminary injunction al…
    STAT · 4mo agoRegulatoryPositive↗ source
  • AI sepsis tools face timing challenges, says STAT AI Prognosis newsletter
    The latest STAT AI Prognosis newsletter notes that current sepsis detection algorithms sometimes require data from future time points, which is unrealistic. The piece highlights how such quirks in…
    STAT · 4mo agoNeutral↗ source
  • Septuagenarian begins family-medicine residency at 72 after 45-year nursing career
    Dawn Zuidgeest-Craft, a former neonatal nurse practitioner, finally entered medical school at age 69 after decades of clinical work and personal life events. She graduated in 2025 and, despite not…
    STAT · 4mo agoPositive↗ source
  • GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review
    GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
    Endpoints · 4mo agoDealPositive↗ source
  • Ending federally funded animal testing could stall xenotransplantation breakthroughs
    Transplant surgeon Joshua Mezrich argues that recent moves to end federally funded animal testing could impede the development of xenotransplantation, a field that aims to use pig organs for human…
    STAT · 4mo agoRegulatoryNegative↗ source
  • GSK to acquire cancer-focused biotech Nuvalent for $10.6 billion
    GSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
    STAT · 4mo agoDealPositive↗ source
  • FDA adds bemotrizinol, first new sunscreen ingredient in 20 years
    The U.S. Food and Drug Administration has approved bemotrizinol as a new active ingredient for over‑the‑counter sunscreens, marking the first addition to the sunscreen monograph since the late 1990…
    fda press · 4mo agoRegulatoryPositive↗ source
  • GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA review
    GSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • U.S. drug shortages drop 23% but average duration climbs to over five years, analysis shows
    The latest U.S. Pharmacopeia analysis reports that the total number of prescription drug shortages fell by 23% last year, marking the second year of decline and the lowest level since 2017. Despit…
    STAT · 4mo agoNegative↗ source
  • Trump’s health-care affordability czar targets hospitals, raises concerns over suppressed alcohol study
    The piece reports that the Trump administration’s health‑care affordability czar has begun scrutinizing hospitals, signaling a new push to control costs and improve price transparency. The czar’s…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA approves first new sunscreen ingredient in over 25 years
    The U.S. Food and Drug Administration has cleared a new sunscreen active called bemotrizinol, the first novel ingredient to receive approval in more than a quarter‑century. The agency said the che…
    STAT · 4mo agoRegulatoryPositive↗ source
  • Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progress
    Grace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Garner Health secures $100 million funding, valuation climbs to $2.7 billion
    Garner Health announced a $100 million financing round that pushes its post‑money valuation to $2.7 billion. The capital raise was completed last month and was led by a group of venture investors.…
    Endpoints · 4mo agoDealPositive↗ source
  • Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioTools
    Treeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipeline
    GSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
    STAT · 4mo agoDealNeutral↗ source
  • Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program
    On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
    Endpoints · 4mo agoDealNeutral↗ source
  • Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trial
    Gilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…
    Endpoints · 4mo agoNeutral↗ source
  • GSK to acquire cancer drug developer Nuvalent for $10.6 billion
    GSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…
    STAT · 4mo agoDealNeutral↗ source
  • Dexcom trial shows continuous glucose monitors improve outcomes across diabetes types
    Dexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to stan…
    STAT · 4mo agoPositive readoutPositive↗ source
  • WuXi AppTec re-added to Pentagon list of firms linked to Chinese military
    WuXi AppTec has been placed again on the Pentagon's updated list of companies that have ties to the Chinese military, according to a June 9, 2026 report. The inclusion marks renewed scrutiny of th…
    Endpoints · 4mo agoRegulatoryNegative↗ source
  • Trump health-care czar touts $510 billion Medicaid cut, warns hospitals of financial strain
    At a Healthcare Financial Management Association conference in National Harbor, Maryland, the Trump administration’s newly appointed health-care affordability czar addressed hospital finance leader…
    STAT · 4mo agoRegulatoryNegative↗ source